Navigation Links
Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes
Date:11/8/2009

MOUNTAIN VIEW, Calif. Nov. 5, 2009 Complete Genomics, a third-generation human genome sequencing company, today announced publication of a report in the journal Science describing its proprietary DNA sequencing platform, including analysis of sequence data from three complete human genomes. The consumables cost for these three genomes sequenced on the proof-of-principle genomic DNA nanoarrays ranged from $8,005 for 87x coverage to $1,726 for 45x coverage for the samples described in this report.

"We've demonstrated that it's possible to accurately and affordably sequence and detect variants across entire human genomes," said Cliff Reid, chairman, president and CEO of Complete Genomics. "This high-quality, cost-effective approach to genome sequencing will allow researchers to study complete genomes from hundreds of patients with a disease to advance the understanding of the genetic causes of that disease, with an end to preventing and treating common human ailments."

The manuscript, titled, "Human Genome Sequencing Using Unchained Base Reads on Self‐assembling DNA Nanoarrays," describes the methodology used to sequence cell lines derived from two individuals previously characterized by the International HapMap project. These included a Caucasian male of European descent (NA07022) and a Yoruban female (NA19240). In addition, researchers sequenced lymphoblast DNA from a Caucasian male sample (NA20431) obtained from the Personal Genome Project (PersonalGenomes.org).

Complete Genomics' proprietary platform enables efficient imaging, while requiring low reagent consumption, through its combinatorial probe anchor ligation (cPAL) chemistry and its use of patterned genomic DNA nanoarrays. With this approach, Complete Genomics' scientists generated high-quality diploid base calls in as much as 95 percent of the genomes sequenced, identifying 3.2 million to 4.5 million sequence variants per genome processed.

Detailed validation of one genome dataset demonstrates a sequence accuracy of just one false variant per 100 kilobases, a remarkably low error rate, particularly for such an affordable technology.

Patterned genomic DNA nanoarrays and 70-base, unchained sequence reads are unique technical achievements. The company's new patterned genomic DNA nanoarrays, which achieve a record high density of 2.85 billion spots per slide at 0.7 micron pitch, will enable Complete Genomics to sequence 10,000 human genomes in 2010.


'/>"/>

Contact: Andrea Long
andreal@waggeneredstrom.com
503-702-8578
Complete Genomics
Source:Eurekalert  

Related biology technology :

1. Dendreon Completes Submission of Biologics License Application for PROVENGE
2. U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma
3. Cardium Completes $6.0 Million Registered Direct Offering
4. Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
5. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
6. Stemedica Completes Meeting with the FDA
7. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
8. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
9. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
10. Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
11. ePDF is Happy to Announce that ePDF has Completed its First Relaunch, and has Come Out as a Beta
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes
(Date:3/28/2017)... , March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. ... pleased to report compelling safety and clinical data from its ... type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment ... ... establishing a complete safety profile at 6 months and showed ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... as Chief Executive Officer with Avomeen Analytical Services. Harvill is a distinguished life ... operations. , Avomeen is a leader in a wide range of services ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the fight against cancer, autoimmune disease and more through a single-cell precision engineering ... and proteomics analysis platform developed in the laboratory of Dr. James Heath ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small ... samples with limited tumor content in a large background of normal or wild ... the need for reliable detection of low abundance somatic mutations, particularly in small ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:2/28/2017)...   Acuant , a leading provider of data ... to new and core technologies building upon the acquisition ... and desktop Acuant FRM TM facial recognition and ... time manual review of identity documents by accredited professionals. ... and most accurate capture software to streamline workflows by ...
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
Breaking Biology News(10 mins):